drugset / Trial / NCT06843967
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Phase 1/2
Recruiting
54 enrolled
Memorial Sloan Kettering Cancer Center
SpringWorks Therapeutics, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
Timeline
- Start
- 2025-02-19
- Primary completion
- 2028-08-19
- Completion
- 2028-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirdametinib | Small molecule | — | — |
| Subject | Palbociclib | Small molecule | — | — |